Exhibit 99.1

(NJ-MEDISCIENCE-TECH)(MDSC-OTCBB) Mediscience Technology Corp.

CHERRY HILL, N.J. Sept. 6, 2005, announced today that it has engaged the
services of a United States investment banking firm as its exclusive placement
agent for a proposed private placement on a best efforts basis of between $6
million and $10 million. The private placement is expected to commence during
the fourth calendar quarter of 2005.

Mediscience Chief Executive Officer Peter Katevatis stated, "We intend to use
the net proceeds of the proposed private placement to fund our ingestible
optical biopsy capable "Camera Pill" (designed to distinguish cancerous,
pre-cancerous, or benign tissues from normal tissue) and initiate FDA clinical
trials for our CD Ratiometer(TM), a medical device designed to detect cervical
cancer on a molecular level and for general corporate purposes.

The proposed Private Placement will not be registered under the Securities Act
of 1933 and may not be offered or sold in the United States absent registration
or an applicable exemption from registration requirement.

                       About Mediscience Technology Corp.
Mediscience Technology Corporation and its New York subsidiary, Medi-photonics
Development Company LLC, are engaged in the design, development and
commercialization of medical devices that detect cancer and physiological change
using frequencies of light that are emitted, scattered and absorbed to
distinguish malignant, precancerous, or benign tissues from normal tissues.
Mediscience's exclusive protected noninvasive technology combines the advantages
of real-time results with enhanced diagnostic sensitivity and specificity
compared with other methods of cancer detection.

                                 Investor Notice
Certain of the matters discussed in this announcement contain forward-looking
statements that involve material risks and uncertainties including market
conditions and FDA approval, which is required before the Camera Pill or the CD
Ratiometer can be sold or licensed for use in the United States. This press
release is intended to comply with Rule 135c promulgated under the Securities
Act of 1933.

                                     Contact
Michael Engelhart, Pres/COO  (201)- 925 5077  mengelhart@mediscience.com
Peter Katevatis Esq.Chairman/ CEO (215)-485-0362  metpk@aol.com